Patents for A61P 35 - Antineoplastic agents (221,099)
01/2010
01/20/2010EP2144930A1 Single chain fc, methods of making and methods of treatment
01/20/2010EP2144923A2 Methods of treatment using glycopegylated g-csf
01/20/2010EP2144909A1 [2, 6]naphthyridines useful as protein kinase inhibitors
01/20/2010EP2144904A1 (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
01/20/2010EP2144893A2 Tricyclic compounds as matrix metalloproteinase inhibitors
01/20/2010EP2144888A1 Methods for treating cancer
01/20/2010EP2144887A1 Dosages and methods for the treatment of cancer
01/20/2010EP2144886A1 Method of treating melanoma
01/20/2010EP2144872A2 Low calcemic, highly antiproliferative, analogs of calcitriol
01/20/2010EP2144871A1 Amidation process for the preparation of cathepsin k inhibitors
01/20/2010EP2144631A2 Multi-functional polyglutamate drug carriers
01/20/2010EP2144628A2 Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
01/20/2010EP2144611A1 Anti-tumor activity of temsirolimus in papillary renal cell cancer
01/20/2010EP2144504A1 Method of treating brain cancer
01/20/2010EP2003140B1 Galactose derivative, drug carrier and medicinal composition
01/20/2010EP1828148B1 Triazole substituted aminobenzophenone compounds
01/20/2010EP1663211B1 Aminotriazole compounds useful as inhibitors of protein kinases
01/20/2010EP1571211B1 Antibodies against lesional tissues
01/20/2010EP1513818B1 Heterocyclic inhibitors of vegfr-2 kinases
01/20/2010EP1487493B1 Conjugates of cytotoxic agents and biologically active peptides
01/20/2010EP1456160B1 Vitamin d analogues
01/20/2010EP1443970B1 Promoters exhibiting endothelial cell specificity and methods of using same
01/20/2010EP1427396B1 Dosage forms having prolonged active ingredient release
01/20/2010EP1202961B1 Arylsulfonamido-substituted hydroxamic acid derivatives
01/20/2010EP1117419B1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions
01/20/2010EP1077994B1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
01/20/2010EP0917538B1 Eukaryotic cells expressing at their surface at least an hla-g isoform and their applications
01/20/2010CN101628111A TACI-immunoglobulin fusion proteins
01/20/2010CN100582112C 4-aminothieno [2,3-d] pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors
01/20/2010CN100582110C Cyclohexanone analog saturated triring(bridge)compound and its preparation method and uses
01/20/2010CN100582101C Antitumoral agent
01/20/2010CN100582084C Hydrophobic polyamine analogs and methods for their use
01/20/2010CN100581589C Radioactively labelled amino acid analogues, their preparation and use
01/20/2010CN100581585C Novel remedies for cancer
01/20/2010CN100581584C Serine protease inhibitor of Rana grahami, and its application
01/20/2010CN100581582C Compound oral taking preparation of cantharis, and preparation method
01/20/2010CN100581570C Traditional Chinese medicine decoction
01/20/2010CN100581556C Chinese traditional extraction and the function containing dammarane type four-ring triterpene sapogenin
01/20/2010CN100581545C Siromosi medicinal composition and its making method
01/20/2010CN100581539C Effective component of hedyotis diffusa and method of preparing the same and application
01/20/2010CN100581374C Waxberry tea and its preparation method
01/19/2010USRE41084 Rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methyl propionic acid (CCI-779) and 4-dimethylamino-but-2-enoic acid(4-(3-chloro-4-fluoro-phenylamino)-3-cyano-7-ethoxy-quinol in-6-yl)amide (EKB-569); synergistic; antitumor agents
01/19/2010US7649095 Piperidine derivatives and agent comprising the derivative as active ingredient
01/19/2010US7649012 Compounds, pharmaceutical compositions containing same, and methods of use for same
01/19/2010US7649001 Fused benzene derivative and use
01/19/2010US7649000 (2'S,2''R)-4-(2'-(2''-amino-3''-(4'''-ethoxyphenyl)propanoylamino)-3'-phenylpropanoyl-amino)piperidine- 1-carboxamidine; inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation
01/19/2010US7648999 Activator for peroxisome proliferator-activated receptor δ
01/19/2010US7648988 6-Chloro-2-piperazino-4-pyrrolidinopteridine derivatives; brain, nervous system, respiratory system, gastrointestinal, and psychological disorders; arthritis, antiasthmatics, cancer, leukemia, pain; Crohn's, Alzheimer's, and Parkinson's disease; multiple sclerosis; joint, eye and skin disorders
01/19/2010US7648986 Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine
01/19/2010US7648975 Macrocyclic quinazoline derivatives as antiproliferative agents
01/19/2010US7648826 Detecting CYP24 expression level as a marker for predisposition to cancer
01/19/2010US7648703 Combination of anti-EP-CAM antibody with a chemotherapeutic agent
01/19/2010US7648702 Suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin; containing polypeptide with an aggregation inhibitor selected from the group consisting of L-arginine and L-cysteine.
01/19/2010US7648695 A halogenated xanthene derivative, preferably Rose Bengal; can be delivered at high concentrations to certain tissues
01/19/2010CA2466869C Methods and compositions for ameliorating the undesirable effects of chemotherapy
01/19/2010CA2439268C Combination comprising a signal transduction inhibitor and an epothilone derivative
01/19/2010CA2427177C Process for preparing distamycin derivatives
01/19/2010CA2420026C 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
01/19/2010CA2315897C Novel camptothecin tetracyclic analogues, preparation, methods, applications as medicines and pharmaceutical compositions containing them
01/19/2010CA2239904C Inhibitors of interleukin-1.beta. converting enzyme
01/14/2010WO2010006343A2 Glycopeptide constructs and uses thereof
01/14/2010WO2010006315A2 Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents
01/14/2010WO2010006234A2 Anticancer oral formulation
01/14/2010WO2010006172A2 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs
01/14/2010WO2010006169A2 2-methylene-19, 26-dinor-(20s, 22e, 25r)-vitamin d analogs
01/14/2010WO2010006153A2 Topopyrones: dual topoisomerase inhibitors
01/14/2010WO2010006136A2 Adenovirus targeting
01/14/2010WO2010006135A2 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs
01/14/2010WO2010006125A2 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs
01/14/2010WO2010006123A2 19-nor-vitamin d analogs with 1,2-dihydrofuran ring
01/14/2010WO2010006121A2 19-nor-vitamin d analogs with 3,2-dihydrofuran ring
01/14/2010WO2010006086A2 Kinase inhibitors and methods of use
01/14/2010WO2010005958A2 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
01/14/2010WO2010005879A1 Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
01/14/2010WO2010005876A2 Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
01/14/2010WO2010005807A2 Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
01/14/2010WO2010005799A2 Novel acetates of 2-deoxy monosaccharides with anticancer activity
01/14/2010WO2010005740A2 Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
01/14/2010WO2010005735A2 Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment
01/14/2010WO2010005726A2 Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
01/14/2010WO2010005725A2 Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
01/14/2010WO2010005704A2 Novel helper plasmid, defective sindbis viral vectors and methods of use thereof
01/14/2010WO2010005697A2 18f-labelled three-and four-carbon acids for pet imaging
01/14/2010WO2010005693A1 Cyclized ngr peptide compounds, compositions, and methods of their use
01/14/2010WO2010005585A2 4-aminoquinazoline prodrugs
01/14/2010WO2010005558A2 Pi3k isoform selective inhibitors
01/14/2010WO2010005534A2 Proteasome inhibitors for selectively inducing apoptosis in cancer cells
01/14/2010WO2010005069A1 Immunity-inducing agent and method for detection of cancer
01/14/2010WO2010005068A1 Pharmaceutical composition for treatment and prevention of cancer
01/14/2010WO2010005055A1 Oligonucleotide structure, and method for regulation of gene expression
01/14/2010WO2010005047A1 Intestinal environment-improving agent
01/14/2010WO2010005046A1 Anti-angiogenic agent
01/14/2010WO2010004761A1 Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
01/14/2010WO2010004512A2 Dicabba-analogues of octreotide
01/14/2010WO2010004339A1 Processes for the preparation of crystalline forms of sunitinib malate
01/14/2010WO2010004337A1 Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed
01/14/2010WO2010004215A2 Substituted 1-benzyl-cinnolin-4(1h)-one derivatives, preparation thereof, and therapeutic use thereof
01/14/2010WO2010004204A2 Fgf-r4 receptor-specific antagonists
01/14/2010WO2010004198A2 Antineoplastic derivatives, preparation thereof, and therapeutic use thereof
01/14/2010WO2010004197A2 Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof